

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

AQUACELL TECHNOLOGIES INC
Form 10KSB
October 12, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 10-KSB

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2005

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number 1-16165

AQUACELL TECHNOLOGIES, INC.

(Name of small business issuer in its charter)

Delaware

33-0750453

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

10410 Trademark Street, Rancho Cucamonga, CA

91730

(Address of principal executive offices)

(Zip Code)

Issuer's telephone number: (909) 987-0456

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value \$.001 per share

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the issuer was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days. Yes ☒ No ☐

Check if there is no disclosure of delinquent filers pursuant to Item 405 of
Regulation S-B contained herein, and will not be contained, to the best of
issuer's knowledge, in definitive proxy or information statements incorporated
by reference in Part III of this Form 10-KSB or any amendment to this Form
10-KSB. ☒

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

The information required in Part III by Items 9, 10, 11, 12, and 14 is incorporated by reference to the issuer's proxy statement in connection with the 2004 Annual Meeting of Shareholders, which will be filed by the issuer within 120 days after the close of its fiscal year.

State issuer's revenues for its most recent fiscal year: \$837,000.00.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 5, 2005, the aggregate market value of the issuer's Common Stock (based on its reported last sale price on the American Stock Exchange) held by non-affiliates of the issuer was \$9,426,042.

At October 5, 2005, 22,638,643 shares of issuer's Common Stock were outstanding.

PART I

ITEM 1. BUSINESS

AquaCell Technologies, Inc. (the "Company") was incorporated in Delaware on March 19, 1997. The Company has two operating subsidiaries, AquaCell Media, Inc., which operates in the out-of-home advertising segment of the advertising industry, and Aquacell Water Inc. (formerly Water Science Technologies, Inc.), which is engaged in the manufacture and sale of products for water filtration and purification, addressing various water treatment applications for municipal, industrial, commercial, and institutional purposes.

AquaCell Media, Inc.

In 2004, we revised our business model for our patented self-filling water cooler, transitioning away from merely selling and leasing our patented, self-filling water coolers. Our focus is now to place the cooler in a retail location, preferably dealing with large chain operations to secure multiple locations, and then selling advertising space on the cooler's permanently attached bottled to third parties.

We install our patented Aquacell Bottled Water Cooler System free of charge to the various locations and retain ownership of the coolers, generating revenue through the sale of advertising on the label of the cooler's permanently attached five-gallon bottle. We are, in effect, creating a water cooler billboard, whereby advertisers put their targeted message on the bottle. Since the water cooler is a known congregating location, it is an excellent venue for advertisers.

Since inception of the program in 2004, we have placed approximately 1,400 "billboard" water coolers into chain drug stores and other locations and have sold advertising to large household name advertisers. We are presently negotiating with several chain stores to secure additional locations.

Out-of-Home Advertising Industry

In July 2005, the Wall Street Journal reported that advertising industry executives see out-of-home as one of the hottest advertising media this year, according to a recent survey by the American Association of Advertising Agencies, behind only online and the placement of brands within entertainment programming.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

In September 2005, Advertising Age reported that advertisers' demand for out-of-home advertising alternatives is surging, as advertisers' concern about the fragmentation of TV audiences and their tuning out of broadcast messages increases. Viacom stated that television networks recognize that they can no longer self-promote with television advertising and are actively promoting their shows with non-traditional out-of-home advertising.

Out-of-home advertising encompasses all forms of advertising that target consumers while they're on the go. All areas of out-of home advertising are growing as advertisers seek to reach consumers closer to the point of purchase.

One sector of out-of-home advertising is "in-store" advertising. According to Advertising Age, retailers and marketers have transformed retail stores into a media channel. Although in-store promotions and point-of-purchase displays have been around for many years, it has only recently been transformed into a new form of advertising. This transformation may be attributed to marketing studies conducted by Point-of-purchase Advertising International, (POPAI), beginning in 2001 which conclusively showed that point-of-purchase advertising is compatible with other advertising means and can increase sales volumes significantly. POPAI has found that 50 to 70% of all buying decisions are made at the point of purchase, and that in-store marketing plays a large role in changing customer behavior and attitudes.

In-store advertising is primarily dominated by floor and shelf advertising, which has demonstrated that such advertising increases sales of the advertised products by 15% to 35%. According to Inc. magazine, revenues

2

of FloorGraphics, the pioneer of in-store floor advertising grew 7,500% over a five-year period from its inception in 1998 to \$75 million.

Our Water Cooler Billboard

Our Aquacell Bottled Water Cooler System looks like a traditional five-gallon bottled water cooler, but it is actually a self-contained water filtration, bottling and dispensing system in one. The Aquacell cooler is connected to a standard municipal water supply. The water is filtered and disinfected through multiple step systems and the treated water then automatically fills the permanently attached five-gallon bottle on the cooler as water is dispensed. Our patents pertain to the attachment of the bottle to the cooler, and the float valve in the bottle, providing the automatic refilling.

The permanently attached five-gallon bottle is significant to our marketing strategies, as it provides an ideal location for advertisement. And, since the bottle is permanently attached, there are no bottles to store and employees do not have to change the bottle allowing customers to always find the bottle full. We primarily utilize the services of The ICEE Company for installation and service, and to a lesser extent, Roto-Rooter Plumbers.

Our Advertising Program

Our "billboard" water coolers have been installed into chain drug stores and other various locations - primarily in Rite Aid nationwide and in New York based Duane Reade stores. We are in discussions with other national chain stores, and expect to add a significant number of locations to our network over the next year.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Since the bottle is permanently attached to the water cooler, the label remains intact throughout the advertising campaign. Advantages of our cooler advertising program include: increased sales of advertised products; targeted advertising; ad gets face-to-face impact; advertisers have exclusivity with no clutter from competing ads; advertisement of products available for sale in the store reaches the consumers at the apex of their purchase intent cycle; long viewing time - since pages can't be turned, there is no channel surfing or mouse clicking.

Our first advertiser was Unilever, who advertised Dove Cool Moisture on our water coolers as a part of its initial product launch. Unilever reported an average 34% sales lift of the product in Duane Reade stores carrying the cooler ads versus stores without cooler ads. Through the Unilever advertising, we were approached by CBS to promote its new comedy "Out of Practice" on our coolers installed in stores in the New York and Los Angeles areas. Advertising is typically contracted for on a purchase order basis.

We are in discussions with a number of companies and/or their advertising agencies for future advertising on our billboard coolers. We believe we are competitively priced with other out-of-home advertising options as measured in cost-per-thousand, and are priced significantly below television, radio and print advertising, which should help us capture a share of this growing industry segment.

Aquacell Water, Inc.

In March 2002 AquaCell Technologies acquired Water Science Technologies (WST) and in August 2005 we changed its name to Aquacell Water, Inc., at which time we replaced the president and former owner of that company with a new management team.

Aquacell Water manufactures custom designed turnkey water purification and treatment systems for municipal, industrial, commercial and institutional applications. Depending upon the source of the water - ground water, surface water or seawater - its content and the required quality of the treated water, Aquacell Water builds a custom system designed to meet the specifications of the end user. We engineer and design the systems we produce to ensure that we meet the needs of our customers, and provide installation, maintenance and training.

3

We integrate various technologies - including dealkalization, deionization, desalination, carbon filtration, multimedia filtration, ozonation, reverse osmosis, ultrafiltration, ultraviolet light disinfection and water softening-combined with pumps, valves and control panels to provide the ideal system for the customer's needs.

We have built and installed systems around the world for a myriad of applications including water bottling plants, manufacturing facilities, restaurants and food processing, car washes and many more.

Given the custom nature of our business, we do not have a standard product line nor do we carry a finished goods inventory and have a limited inventory of raw materials.

Water Purification Industry Background

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Warning of a mounting water crisis, the United Nations designated 2003 as the "International Year of Freshwater", stating, "Water is likely to become a growing source of tension and fierce competition between nations if present trends continue..." The UN has reported that more than half of humanity will be living with water shortages within 50 years. According to a report from scientists at the International Water Management Institute, the risk of wars being fought over water is rising because of explosive global population growth and widespread complacency. It has been suggested, however, that employing water purification systems, including desalination plants, in areas of the world lacking fresh drinking water, could avert such wars.

The highly fragmented water purification industry has thousands of companies involved in various capacities, including companies which design fully integrated systems for processing millions of gallons of water for municipal, industrial, and commercial applications, down to the independent water delivery route person.

According to an article appearing in The Wall Street Journal, water supply businesses generate approximately \$400 billion in revenue worldwide annually. Demand for water purification has continued to grow nationally and internationally due to economic expansion, scarcity of usable water, concern about water quality and regulatory requirements.

Municipal Water Treatment

In the United States, new federal standards for drinking water are requiring community water systems to be significantly upgraded. Each year, more than 50 million people in the United States are exposed to contaminated municipal water necessitating "boil water alerts" to be issued.

The Safe Drinking Water Act requires municipalities to comply with federally mandated minimum contaminant levels of a number of impurities. As awareness of health issues brought about by contaminants in drinking water increase, the EPA is often forced to lower the allowable levels of certain contaminants, requiring municipalities to upgrade their systems.

In January 2006, municipalities will be required to be in compliance with a mandate lowering the allowable level of arsenic in drinking water from 50 parts-per-billion to 10. Aquacell Water provides a proprietary process for removing arsenic from drinking water with zero wastewater discharge requiring no onsite chemical. This process reduces both the capital and operating costs for municipalities. We anticipate that this same process can be used to treat other waterborne contaminants.

Additionally, costs for protection stemming from potential terrorism will cost \$450 million for Congressional ordered vulnerability studies, with an additional \$1.6 billion needed for basic security at pumping stations and treatment plants. The August 12, 2004 Review-Journal of Las Vegas reported that it had obtained a bulletin issued by the FBI and Department of Homeland Security reporting that terrorists discussed a plot to recruit employees of water treatment facilities to poison drinking supplies during the chlorination process in hopes of causing mass casualties.

Industrial Water Treatment

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Nearly every product manufactured requires some level of water purification or wastewater treatment. While some industries only require basic treatment, such as for cooling towers and boiler feed water, others require ultra-pure water for specific sensitive processes or products, as in the micro-chip and pharmaceutical industries.

Aquacell Water has custom designed water treatment systems to meet the needs of numerous manufacturers including textile manufacturing, manufacturers, food processing, beverage manufacturer/bottlers and many others.

Commercial Water Treatment

Water treatment systems designed for commercial applications range from simple treatment systems designed to protect equipment to purifying water for consumption.

Aquacell Water manufactures water treatment systems to address various commercial applications including car washes, aqua farming, resorts, restaurants, water bottlers and water stores and more.

Institutional Water Treatment

Institutions have varying needs for different levels of water treatment and purification. These needs range from treated water for boilers, laundry services and food/beverage serves, to purified water for medical procedures.

Exposure to microbial waterborne contaminants can cause serious illness and potential death in individuals with immune system deficiencies, such as those with AIDS, cancer patients and organ transplant recipients. In addition, the elderly and very young children can be at risk if they consume contaminated water.

Aquacell Water designs and builds water treatment systems for institutional applications such as hospitals, nursing homes, prisons and schools.

Customers

Our AquaCell Media subsidiary customers include any company seeking to advertise its products or services and/or the agencies that represent them, for the purchase of advertising on our Aquacell Bottled Water Cooler Systems installed in retail and other strategic locations. To date, advertisers include Unilever and CBS Television.

Our Aquacell Water customers include a broad range of industries including municipalities, manufacturers, various commercial clients such as water bottlers and car washes and institutions such as hospitals. We have built systems for companies including Allied Signal, Intel, National Semiconductor, Motorola, General Motors, Boeing, Russell Athletic, Safeway Foods and many other international corporate customers as well as the Canadian and US Federal governments and local governments.

Production, Raw Materials and Supplies

Our products are manufactured in our 10,000 square foot manufacturing facility located in Rancho Cucamonga, California, and the Aquacell Water 8,300 square foot facility located in Tempe, Arizona. Our California plant is located within a 100-mile radius of 95% of our suppliers allowing for just-in-time inventory.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Our facilities utilize manufacturing processes that follow the guidelines of the Water Quality Association. The manufacturing process of our various products includes utilization of injection-molded parts, for which we own the molds. Multiple vendors have been identified as sources for parts and supplies for our products and we do not anticipate any shortages of such materials.

5

Upon completion of manufacture, each product undergoes quality assurance testing prior to shipping and installation. The raw materials and components used in these products are commonly available commodities such as off the shelf water coolers, water bottles, various fittings, plastic tubing, piping, wiring, valves, sediment filters, reverse osmosis membrane filters, tanks, various filtration media and ultra-violet lights. Our products are fabricated from these materials and assembled together with products bought from other companies to form an integrated product. We do not depend on any single supplier. If any supplier were to become unable to perform, we believe we could readily find a substitute source. We are not a party to any material long-term fixed price supply contracts.

Government Regulation

Federal, state, local and foreign environmental laws and regulations require substantial expenditures and compliance with water quality standards and impose liabilities for noncompliance. We believe that environmental laws and regulations and their enforcement are, and will continue to be, a significant factor affecting the marketability of our products. The treatment of drinking water in the United States is governed by the Safe Drinking Water Act. The 1996 amendments to the Act emphasize risk-based standards for contaminants in drinking water, afford small water supply systems operational flexibility and provide assistance to water system infrastructures through a multi-billion-dollar Drinking Water State Revolving Fund. The Fund program assists public water systems with the financing of the costs of drinking infrastructure that is necessary to achieve or maintain compliance with the Safe Drinking Water Act requirements and to protect public health. The Fund, patterned after the State Revolving Fund contained in the Clean Water Act, provides funding to the states to establish a renewable source of financing for drinking water infrastructure projects. The Fund program is designed to ensure that the drinking water supplies in the United States remain safe and affordable, and that systems that receive funding will be properly operated and maintained. Regulations under the Safe Water Drinking Act also established maximum containment levels for a wide variety of chemicals that may be present in drinking water treatment to meet applicable standards.

Any changes in applicable regulations or their enforcement may affect our operations by imposing additional regulatory compliance costs on our customers, requiring modification of our products or affecting the market for our products. To the extent that demand for our products are created by the need to comply with such enhanced standards or their enforcement, any modification of the standards or their enforcement may reduce demand, thereby adversely affecting our business, financial condition or results of operations. The relaxation or repeal of any such laws or regulations or the strict enforcement thereof could also adversely affect our business and prospects. Conversely, changes in applicable environmental requirements imposing additional regulatory compliance requirements or causing stricter enforcement of these laws or regulations could increase the demand for our products.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Competition

The water purification industry is fragmented and highly competitive due to the large number of businesses within certain product areas. We compete with many companies that have greater market penetration, depth of product line, resources and access to capital, all of which could be competitive advantages. Competitors of our Aquacell Water subsidiary include water filtration systems manufacturers such as General Electric and US Filter.

The out-of-home advertising industry is highly competitive. We compete with many companies that have greater market penetration, depth of product offering, resources and access to capital, all of which could be competitive advantages. Competitors in the out-of-home advertising industry include Viacom and Clear Channel, while more specific in-store advertising competitors include News Corp's News America/Smart Source and FloorGraphics, Inc.

While we believe that we can deliver our products on an economically competitive basis, there can be no assurance in that regard. In addition, many competitors have greater financial resources than us to finance their expansion

6

and internal growth opportunities. Consequently, we may encounter significant competition in our efforts to achieve our strategic goals. There can be no assurance that our competitors will not develop products that are superior to ours or achieve greater market acceptance than our products. Competition could have a material adverse effect on our ability to consummate arrangements with customers or enter into strategic business alliances. Moreover, in response to changes in the competitive environment, we may make certain pricing, service or marketing decisions or enter into acquisitions or new ventures that could have a material adverse effect on our business, financial condition and results of operations.

Intellectual Property

We own a United States and Canadian patent on our automatic-refilling purified bottle water cooler. These patents do not expire until November 20, 2006 and October 2, 2009, respectively. We have filed for two patents with the US Patent and Trademark office, which if granted, would provide exclusive rights for utilizing the water cooler bottle as an advertising mechanism. We have pending applications to federally register our "Never Change Another Bottle" logo and AquaCell marks. We also conduct business in California under the name Global Water Solutions, Inc. We intend to seek appropriate additional trademark or service mark registrations in connection with our product and service offerings.

Employees

As of June 30, 2005 we had 20 employees. None of our employees are covered under collective bargaining agreements although we do have employment agreements with certain executives. Management believes we maintain a good relationship with our employees.

ITEM 2. PROPERTIES

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Our principal executive office and our 10,000 square foot manufacturing facility are located in Rancho Cucamonga, California under a five-year lease that commenced on January 1, 1999 and expires on April 30, 2006, following two extensions. That lease has an annual base rent of \$76,800. We also maintain a 7,000 square foot warehouse in Rancho Cucamonga, California under a one-year lease expiring in April 2006. That lease has an annual rent of \$40,800. We also maintain an 8,300 square foot Aquacell Water manufacturing facility in Tempe, Arizona under a five (5) year lease that commenced on November 1, 2001 and expires on October 31, 2006. That lease has an average annual base rent of \$55,900. We believe that, if necessary, alternative space is readily available at comparable rates and on comparable terms with respect to all of our leased properties. We also believe that we can obtain additional space necessary to support increases in our future operation. We believe that the properties described above are currently protected by adequate insurance.

ITEM 3. LEGAL PROCEEDINGS

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

7

PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The Company's Common Stock commenced quotation on the American Stock Exchange on February 12, 2001 following its initial public offering. The following table sets forth, for the periods indicated, the last sale prices for the Common Stock as reported by American Stock Exchange:

Period	High (\$)	Low (\$)
-----	-----	-----
Fiscal 2006		
10/1/05 - 10/10/05.....	\$ 0.53	\$ 0.50
First Quarter.....	0.68	0.36
Fiscal 2005		
Fourth Quarter.....	\$ 0.44	\$ 0.33
Third Quarter.....	0.66	0.35
Second Quarter.....	0.91	0.38
First Quarter.....	0.90	0.58
Fiscal 2004		
Fourth Quarter.....	\$ 1.72	\$ 0.82
Third Quarter.....	1.92	1.20
Second Quarter.....	2.84	1.20
First Quarter.....	3.05	2.06

On October 10, 2005, the last sale price of the Common Stock as reported by AMEX was \$0.52. On September 30, 2005, there were approximately 170 holders of record of the Company's Common Stock and, the Company believes, over 1,600 beneficial owners of the Company's Common Stock.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Depending upon the Company's capital resources and needs, the Company has no present plans to pay cash dividends in the future. The payment of dividends on common stock, if any, in the future is within the discretion of the Board of Directors and will depend upon the Company's earnings, its capital requirements and financial condition, and other relevant factors, although this may change based upon the foregoing factors.

8

Recent Sales of Unregistered Securities

During the year ended June 30, 2005, the Company made the following sales of unregistered securities:

Date of Sale	Title of Security	Number Sold	Consideration Received and Description of Underwriting or Other Discounts to Market Price Afforded to Purchasers	Exemption From Registration Claimed	If Co Te
4/7/05	Common Stock	50,334	Issued upon exercise of warrants.	4 (2); 4 (6)	
4/7/05	Warrants to Purchase Common Stock	50,334	Issued in connection with repricing of certain warrants issued on 6/30/04 to \$0.32- no cash until exercise.	4 (2); 4 (6)	Al
4/19 & 4/24/05	Common Stock	416,667	Issued in connection with private placement at \$0.30 per share.	4 (2); 4 (6)	
4/19 & 4/24/05	Warrants to Purchase Common Stock	416,667	Issued in connection with private placement- no cash until exercise.	4 (2); 4 (6)	Al
6/30/05	Class B Preferred	718,000	Issued in connection with private placement of Class B Preferred stock.	4 (2); 4 (6)	
6/30/05	Warrants to Purchase Common Stock	304,391	Issued in connection with private placement of Class B Preferred stock including 24,891 to placement agent- no cash until exercise.	4 (2); 4 (6)	Al

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

When used in this Form 10-KSB and in future filings by the Company with the Commission, statements identified by the words "believe", "positioned",

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

"estimate", "project", "target", "continue", "will", "intend", "expect", "future", "anticipates", and similar expressions express management's present belief, expectations or intentions regarding the Company's future performance within the meaning of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. The Company has no obligations to publicly release the result of any revisions which may be made to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

Overview

The following discussions and analysis should be read in conjunction with the Company's consolidated financial statements and the notes presented following the consolidated financial statements. The discussion of results, causes and trends should not be construed to imply any conclusion that such results or trends will necessarily continue in the future.

9

AquaCell Technologies, Inc. has two subsidiaries operating in two separate industries. Our AquaCell Media, Inc. subsidiary addresses the out-of-home segment of the advertising industry through the sale of advertising on our patented self-filling water cooler, the Aquacell Bottled Water Cooler System. This business model was launched in 2004, designed to provide us with an on-going revenue model in comparison to selling the coolers, as we had previously done. We install our "billboard" water coolers into retail and other strategic locations free of charge to these locations under five-year contracts, and retain ownership of the cooler. We currently have approximately 1400 coolers installed in Rite Aid and Duane Reade drug stores, and have test programs underway in CVS, Kmart/Sears and Winn Dixie. Advertisers to date have been CBS Television and Unilever, who reported a 34% sales lift of its advertised Dove Cool Moisture in stores carrying the cooler ads.

Our Aquacell Water, Inc. subsidiary addresses the municipal, industrial, commercial and institutional sectors of the water treatment and purification industry. We design, manufacture, install and service custom designed turnkey systems that treat from hundreds to millions of gallons of water per day for a variety of applications, including treatment of process water for manufacturing, purification of water for bottling plants and food service, and removal of contaminants from municipal drinking water systems. Our customers range from manufacturers of micro-chips, textiles and food and beverage service, to health care providers, defense contractors and the military. The management team of our Aquacell Water subsidiary has over 50 years combined experience in the water treatment industry.

Critical Accounting Policies

The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

expenses, and related disclosure of contingent assets and liabilities. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical experience and all available information. However, future events are subject to change, and the best estimates and judgments routinely require adjustment. US GAAP requires us to make estimates and judgments in several areas, including those related to recording various accruals, income taxes, the useful lives of long-lived assets, such as property and equipment and intangible assets, and potential losses from contingencies and litigation. We believe the policies discussed below are the most critical to our consolidated financial statements because they are affected significantly by management's judgments, assumptions and estimates.

Goodwill:

Goodwill represents the excess of the purchase price over the fair value of net assets of a business acquired. The Company has adopted Statements of Financial Accounting Standards No. 142 (SFAS 142), "Goodwill and Other Intangible Assets". Fair value of the reporting unit is determined by comparing the fair value of the unit with its carrying value, including goodwill. Impairment tests are performed using discounted cash flow analysis and estimates of sales proceeds. The annual evaluation of goodwill is performed at June 30th, the end of the Company's fiscal year. Impairment changes were \$74,000 and \$218,000 for the years ended June 30, 2005 and 2004.

Income taxes:

The Company accounts for income taxes using the asset and liability method described on SFAS No. 109, "Accounting For Income Taxes", the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company's assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than no that some portion or all of the deferred tax assets will not be realized.

10

Long-lived assets:

The Company accounts for the impairment and disposition of long-lived assets in accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-lived Assets." In accordance with SFAS No. 144, long-lived assets to be held are reviewed whenever events or changes in circumstances indicate that their carrying value may not be recoverable. The Company periodically reviews the carrying value of long-lived assets to determine whether or not an impairment to such value has occurred, and has determined that as of June 30, 2005 that impairment, where appropriate, was recorded in the financial statements.

New Accounting Pronouncements:

In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Share-Based Payment." SFAS 123 (R) addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments. SFAS 123 (R) requires an entity to recognize the grant-date fair-value of stock options and other equity-based compensation issued to employees in the income statement. The

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

revised statement generally requires that an entity account for those transactions using the fair-value-based method, and eliminates the intrinsic value method of accounting in APB 25, which was permitted under SFAS No. 123, as originally issued.

The revised statement requires entities to disclose information about the nature of the share-based payment transactions and the effects of those transactions on the financial statements.

SFAS No. 123 (R) is effective for small business issuer's financial statements for the first interim or annual reporting period that begins after December 15, 2005, with early adoption encouraged.

The Company is currently evaluating the impact that this statement will have on its financial condition or results of operations.

Results of Operations

For the year ended June 30, 2005 on a consolidated basis, revenues were \$837,000, representing an increase of \$108,000, or 15%, over the preceding year, resulting primarily from our initial advertising revenues of \$30,000 and an increase in sales by our Aquacell Water subsidiary of \$83,000. Cost of sales was 66% for the year ended June 30, 2005 as compared to 74% for the prior year. The decrease in cost of sales percentage resulted from spreading manufacturing cost over an increased sales volume from our Aquacell Water subsidiary.

Net loss on a consolidated basis, attributable to common stockholders, for the year ended June 30, 2005 decreased to \$4,001,000 or \$0.24 per share, as compared to \$4,562,000 or \$.40 per share, for the prior year representing a 12% reduction of net loss. The decrease in the loss is primarily attributable to the decrease in impairment loss on goodwill of \$144,000, a fair value adjustment of a derivative in the amount of \$333,000, and write-off of accrued interest on notes receivable in the amount of \$48,000.

Salaries and wages decreased by \$20,000 for the year ended June 30, 2005 over the prior year resulting primarily from bonuses paid in the prior year. Legal, accounting and other professional expenses increased by approximately \$60,000 for the year ended June 30, 2005 resulting primarily from independent consulting services. Stock based compensation increased by \$101,000 to \$1,173,000 for the year ended June 30, 2005 resulting from a write-off of warrants, related to certain consulting agreements, issued during prior years. Other costs and expenses decreased by approximately \$109,000, or 6% to \$1,593,000 for the year ended June 30, 2005. Current period expenses consisted primarily of manufacturing costs- billboard coolers-\$481,000; rent-\$100,000; telephone and utilities-\$46,000; travel-\$81,000; business promotion-\$102,000; insurance- \$91,000; and vehicle expenses-\$84,000.

Liquidity and Capital Resources

The Company has developed a plan to address liquidity, in connection with its ability to continue as a going concern, in several ways. It intends to continue to raise capital through the sale or exercise of equity securities. Toward that end the Company raised net equity of approximately \$1,549,000 through the exercise of warrants to purchase common shares and private placements of common shares and Series B Convertible Preferred stock during the year ended June 30, 2005. The Company has continued to pursue the placement of

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

its water cooler billboards in various locations and the Company is seeking to increase its revenues through the sale of advertising on the band of the cooler's permanently attached five-gallon bottle as outlined in the Overview section of Management's Discussion.

Cash used by operations during the year ended June 30, 2005 amounted to \$1,947,000. Net loss of \$3,888,000 was reduced by impairment loss on goodwill of \$74,000, non-cash stock based compensation in the amount of \$1,173,000, depreciation and amortization of \$79,000 and a bad debt provision of \$15,000. Net loss was further decreased by increases in accounts payable of \$205,000, accrued liabilities of \$368,000 and by net changes in prepaid expenses, customer deposits, accounts receivable and inventories aggregating \$27,000.

Cash used by investing activities during the year ended June 30, 2005 represented capital expenditures in the amount of \$471,000 primarily for billboard coolers and by payments on notes issued for the purchase of equipment in the amount of \$3,000.

Cash provided by financing activities was approximately \$1,653,000. Proceeds from private placements of common and Preferred B stock amounted to \$448,000 and expenses were \$24,000. Proceeds from exercises of common stock purchase warrants amounted to \$1,269,000 and expenses amounted to \$144,000. Proceeds from subscriptions receivable were \$40,000. Loans from related parties amounted to \$100,000 and the Company paid dividends of Series B Preferred stock in the amount of \$36,000.

We have granted warrants, subsequent to our initial public offering, in connection with private placements, consulting, marketing and financing agreements that remain outstanding at the date of this filing and may generate additional capital of up to approximately \$12,392,000 if exercised. As of June 30, 2005, 250,000 warrants generating \$39,000 were in the money and 7,946,000 warrants generating \$12,353,000 were out of the money. Historically, the Company has repriced out of the money warrants issued in connection with equity placements to generate additional capital. There is no assurance however, that any of the warrants will be exercised.

In December 2004, we were notified by the American Stock Exchange that the Amex accepted the Company's 18-month plan (the "Plan") for continued listing, in connection with the Amex's listing requirements, following receipt of notification of non-compliance with the Amex's minimum stockholder equity requirement. The Plan was evaluated and accepted by the Amex, indicating that the Company made a reasonable demonstration of an ability to regain compliance with the continued listing standards within the allotted time frame.

During December 2004, the Company announced the spin-off of its inactive Aquacell Water subsidiary to its common stockholders on a share for share basis. It was anticipated that Aquacell Water might acquire our Water Science Technologies, Inc. subsidiary. On July 19, 2005 the Board of Directors approved that, in place of the Company's spin-off of its inactive Aquacell Water subsidiary, management reincorporate its Water Science Technologies subsidiary in Delaware and change its name to Aquacell Water, Inc. Furthermore, this subsidiary will file a Form 10 registration statement with the possibility of spinning this company off to the AquaCell Technologies, Inc.'s common stockholders on a share for share basis. However, there is no assurance that this spin-off will occur.

At June 30, 2005 five tax liens have been filed; two Federal tax liens against the Company in the amount of \$98,000, a Federal tax lien against an inactive subsidiary in the amount of \$76,000, a Federal tax lien against another subsidiary in the amount of \$118,000 and a state tax lien against the inactive subsidiary in the amount of \$26,000. We are in negotiations to reach settlement agreements with the appropriate tax agencies. There are no

assurances that these negotiations will result in successful agreements and the Company's assets could be subject to enforcement action.

Management believes that its present cash position combined with subsequent equity raises and conversion of warrants and cash flows expected to be generated from future operations will be sufficient to meet presently anticipated needs for working capital and capital expenditures through at least the next 12 months; however, there can be no assurance in that regard. The Company presently has no material commitments for future capital expenditures and internally generated cash flows expected from future operations.

ITEM 7. FINANCIAL STATEMENTS

See Financial Statements beginning on page F-1.

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 8A. CONTROLS AND PROCEDURES

Within the 90 days prior to the date of this Report the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's chief executive officer and chief financial officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Rule 13a-14 adopted under the Securities Exchange Act of 1934. Based upon that evaluation, the chief executive officer and chief financial officer concluded that the Company's disclosure controls and procedures are effective. There were no significant changes in the Company's internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation.

ITEM 8B. OTHER INFORMATION

None.

PART III

ITEM 9. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

See Item 14.

ITEM 10. EXECUTIVE COMPENSATION

See Item 14.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

See Item 14.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

See Item 14.

ITEM 13. EXHIBITS

See Exhibit Index.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by Items 9, 10, 11, 12, and 14 is incorporated by reference to the information included in the Company's definitive proxy statement in connection with the 2004 Annual Meeting of Stockholders.

14

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 11, 1005

AQUACELL TECHNOLOGIES, INC.
(Registrant)

By: /s/ JAMES C. WITHAM

Name: James C. Witham
Title: Chief Executive Officer

In accordance with the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signatures -----	Title -----	Date ----
/s/ James C. Witham ----- James C. Witham	Chairman of the Board of Directors and Chief Executive Officer (Principal Executive Officer)	October 11, 1005
/s/ Karen B. Laustsen ----- Karen B. Laustsen	Director and President	October 11, 1005

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

/s/ Gary S. Wolff ----- Gary S. Wolff	Director and Chief Financial Officer (and Principal Accounting Officer)	October 11, 1005
---	--	------------------

/s/ Glenn Bergenfield ----- Glenn Bergenfield	Director	October 11, 1005
---	----------	------------------

/s/ Dr. William DiTuro ----- Dr. William DiTuro	Director	October 11, 1005
---	----------	------------------

/s/ James Barton ----- James Barton	Director	October 11, 1005
---	----------	------------------

15

EXHIBIT INDEX

Exhibit Number	Description
31.1	Chief Executive Officer's Certification Pursuant to Rule 13A-14 and 15D-14 Under the Securities Exchange Act of 1934, As Amended
31.2	Chief Financial Officer's Certification Pursuant to Rule 13A-14 and 15D-14 Under the Securities Exchange Act of 1934, As Amended
32.1	Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

16

AQUACELL TECHNOLOGIES, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.....	F-1
FINANCIAL STATEMENTS	
Consolidated Balance Sheet, June 30, 2005.....	F-2
Consolidated Statements of Operations for the years ended June 30, 2005 and 2004.....	F-3
Consolidated Statements of Stockholders' Equity (Deficiency)	

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

for the years ended June 30, 2005 and 2004.....	F-4
Consolidated Statements of Cash Flows for the years ended June 30, 2005 and 2004.....	F-6
Notes to Consolidated Financial Statements.....	F-8

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors of
AquaCell Technologies, Inc.

We have audited the accompanying consolidated balance sheet of AquaCell Technologies, Inc. and Subsidiaries ("the Company") as of June 30, 2005 and the related consolidated statements of operations, stockholders' equity (deficiency), and cash flows for each of the two years in the period ended June 30, 2005. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Also, an audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of AquaCell Technologies, Inc. and Subsidiaries as of June 30, 2005, and the results of their operations and their cash flows for each of the two years in the period ended June 30, 2005 in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note A to the consolidated financial statements, the Company has incurred significant operating losses for the years ended June 30, 2005 and 2004, and as of June 30, 2005 has a significant working capital deficiency and a stockholders' deficiency that raises substantial doubt about its ability to continue as a going concern. Management's plans regarding those matters are also described in Note A. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ WOLINETZ, LAFAZAN & COMPANY, P.C.

WOLINETZ, LAFAZAN & COMPANY, P.C.

Rockville Centre, New York
October 3, 2005

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

(Except for Note Q (3), as to which the date is October 10, 2005)

F-1

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET June 30, 2005

ASSETS

Current assets:

Cash.....	\$	92,000
Subscription receivable.....		148,000
Accounts receivable, net of allowance of \$17,000.....		59,000
Inventories.....		13,000
Prepaid expenses and other current assets.....		40,000
Total current assets.....		352,000

Property, equipment, and billboard coolers, net..... 1,211,000

Other assets:

Goodwill.....		750,000
Patents, net.....		54,000
Security deposits.....		16,000
Total other assets.....		820,000

\$ 2,383,000

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable.....	\$	787,000
Accrued liabilities.....		1,074,000
Preferred stock dividend payable- Class A.....		2,000
Preferred stock dividend payable- Class B.....		21,000
Customer deposits.....		17,000
Loan payable - related party.....		100,000
Current portion of deferred payable.....		22,000
Total current liabilities.....		2,023,000

Deferred payable, net of current portion..... 451,000

Total liabilities..... 2,474,000

Commitments and contingencies

Stockholders' deficiency:

Preferred stock - Class A, par value \$.001; liquidation preference \$46,000; 1,870,000 shares authorized; 70,000 issued and outstanding.....		-
Preferred stock - Class B, par value \$.001; liquidation preference \$308,000; 4,000,000 shares authorized; 718,000 issued and outstanding.....		1,000
Preferred stock, par value \$.001; 4,130,000 shares authorized; no shares issued.....		-

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Common stock, par value \$.001; 40,000,000 shares authorized; 18,880,465 shares issued and outstanding.....	19,000
Additional paid-in capital.....	22,566,000
Accumulated deficit.....	(21,449,000)

	1,137,000
Unamortized deferred compensation.....	(1,228,000)

Total stockholders' deficiency.....	(91,000)

	\$ 2,383,000
	=====

The accompanying notes are an integral part of these financial statements.

F-2

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

	Year Ended June 30,	
	2005	2004
Revenue:		
Net sales	\$ 807,000	\$ 729,000
Advertising revenue	30,000	-
	-----	-----
	837,000	729,000
	-----	-----
Costs and expenses:		
Cost of sales.....	532,000	542,000
Salaries and wages.....	1,004,000	1,024,000
Legal, accounting and other professional expenses.....	258,000	198,000
Stock based compensation.....	1,173,000	1,072,000
Other.....	1,593,000	1,702,000
Impairment loss on goodwill.....	74,000	218,000
Write-off of notes receivable and accrued interest.....	-	48,000
Fair value adjustment of deferred payable - derivative.....	-	333,000
	-----	-----
	4,634,000	5,137,000
	-----	-----
Loss from operations before other income (expense)	(3,797,000)	(4,408,000)
	-----	-----
Other income (expense):		
Interest expense.....	(91,000)	(106,000)
Interest income.....	-	2,000
	-----	-----
	(91,000)	(104,000)
	-----	-----
Net loss for the year.....	\$ (3,888,000)	\$ (4,512,000)
	=====	=====
Weighted average common shares outstanding - basic and diluted.....	16,724,000	11,396,000
	=====	=====
Loss attributable to common stockholders:		
Net loss.....	\$ (3,888,000)	\$ (4,512,000)
Preferred stock dividends.....	113,000	50,000
	-----	-----

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Loss attributable to common stockholders.....	\$ (4,001,000)	\$ (4,562,000)
	=====	=====
Net loss per common share.....	\$ (0.24)	\$ (0.40)
	=====	=====

The accompanying notes are an integral part of these financial statements.

F-3

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY)

	Preferred Stock- Class A		Preferred Stock- Class B		Common Stock		Additional	Accumu
	Number of Shares	Par Value	Number of Shares	Par Value	Number of Shares	Par Value	Paid-in Capital	Defici
Balances-								
July 1, 2003.....	1,185,000	\$1,000	-	\$ -	8,726,224	\$ 9,000	\$13,544,000	\$ (13,0
Sale of 3,005,204 shares of common stock in connection with private placements, net of costs of \$468,000.....					3,005,204	3,000	3,483,000	
Issuance of 1,400,000 common stock warrants in connection with consulting agreements.....							2,707,000	
Amortization of deferred costs.....								
Conversion of 510,000 shares of Class A preferred stock to 510,000 shares of common stock.....	(510,000)	-			510,000	-		
Dividends on Class A preferred stock.....							(50,000)	
Issuance of 100,000 shares of common stock in connection with service agreement.....					100,000	-	82,000	
Issuance of 2,114,867 shares of common stock upon exercise of common stock warrants, net of expenses of \$79,000..					2,114,867	2,000	783,000	

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Issuance of 35,000 shares of common stock upon exercise of stock options.....					35,000	-	33,000	
Net loss for the year ended June 30, 2004.....								(4,5
Balances- June 30, 2004.....	675,000	1,000	-	-	14,491,295	14,000	20,582,000	(17,5
Issuance of 400,000 shares of common stock in connection with amendment of consulting agreements.....					400,000	1,000	242,000	
Issuance of 150,000 common stock warrants in connection with consulting agreements.....							55,000	
Issuance of 225,000 common stock warrants in connection with amendment of a nonexclusive finders agreement....							143,000 (143,000)	
Issuance of 40,000 shares of common stock as payment of legal fees for filing of a registration statement.....					40,000	-	24,000 (24,000)	
Amortization of deferred costs.....								
Conversion of 605,000 shares of Class A preferred stock to 605,000 shares of common stock.....	(605,000)	(1,000)			605,000	1,000		
Balances forward to F-5	70,000	\$ -	-	\$ -	15,536,295	\$16,000	\$20,879,000	\$ (17,5

The accompanying notes are an integral part of these financial statements.

F-4

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY) -Continued

	Preferred Stock- Class A		Preferred Stock- Class B		Common Stock		Additional	Accumu
	Number of Shares	Par Value	Number of Shares	Par Value	Number of Shares	Par Value	Paid-in Capital	Defici
Balances								
forward from F-4	70,000	\$ -	-	\$ -	15,536,295	\$16,000	\$20,879,000	\$ (17,5
Issuance of 2,275,751 shares of common stock upon exercise of common stock warrants net of expenses of \$144,000.					2,275,751	2,000	1,180,000	
Sale of 983,334 shares of common stock in connection with private placements...					983,334	1,000	294,000	
Issuance of 35,085 shares of common stock as payment of dividends on Class A preferred stock.....					35,085	-	26,000	
Deemed dividends on beneficial conversion feature of preferred stock offering.....							36,000 (36,000)	
Issuance of 50,000 shares of common stock in connection with an employment agreement.					50,000	-	20,000	
Issuance of 25,000 common stock warrants as loan consideration in connection with a loan from a related party.....							5,000	
Issuance of 100,000 common stock warrants in connection with an investor relations agreement.....							19,000	
Sale of 718,000 shares of Class B preferred								

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

stock, net of expenses of \$24,000..	718,000	1,000	-	-	219,000				
Dividends on Class A preferred stock.....					(19,000)				
Dividends on Class B preferred stock.....					(57,000)				
Net loss for the year ended June 30, 2005.....									(3,888,000)
Balances- June 30, 2005	70,000	\$ -	718,000	\$1,000	18,880,465	\$19,000	\$22,566,000	\$ (21,400,000)	

The accompanying notes are an integral part of these financial statements.

F-5

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended June 30,	
	2005	2004
Cash flows from operating activities:		
Net loss.....	\$ (3,888,000)	\$ (4,512,000)
Adjustment to reconcile net loss to net cash used in operating activities:		
Fair value adjustment of deferred payable.....	-	333,000
Impairment loss on goodwill.....	74,000	218,000
Write-off of notes receivable and accrued interest.....	-	48,000
Stock based compensation.....	1,173,000	1,072,000
Provision for bad debts.....	15,000	17,000
Depreciation and amortization.....	79,000	45,000
Changes in:		
Accounts receivable.....	(23,000)	6,000
Accrued interest receivable.....	-	21,000
Prepaid expenses and other current assets.....	13,000	70,000
Inventories.....	81,000	(10,000)
Security deposits.....	-	(2,000)
Accounts payable.....	205,000	(195,000)
Accrued liabilities.....	368,000	203,000
Customer deposits.....	(44,000)	38,000
Net cash used in operating activities.....	(1,947,000)	(2,648,000)
Cash flows from investing activities:		
Payments on notes issued for purchase of property and equipment.....	(3,000)	(4,000)
Collections on notes receivable.....	-	91,000
Capital expenditures.....	(471,000)	(782,000)

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Net cash used in investing activities.....	(474,000)	(695,000)
Cash flows from financing activities:		
Proceeds (repayments) of loans from related parties.....	100,000	(80,000)
Proceeds from private placements of Class B preferred stock.....	153,000	-
Proceeds from private placements of common stock.....	295,000	3,954,000
Expenses of stock offerings.....	(24,000)	(468,000)
Preferred stock dividends paid- Class A.....	-	(53,000)
Preferred stock dividends paid- Class B.....	(36,000)	-
Proceeds from subscriptions receivable.....	40,000	-
Proceeds from exercise of stock options.....	-	33,000
Proceeds from exercise of common stock warrants.....	1,269,000	864,000
Expense of warrant exercise.....	(144,000)	(79,000)
Net cash provided by financing activities.....	1,653,000	4,171,000
Increase (decrease) in cash.....	(768,000)	828,000
Cash, beginning of year.....	860,000	32,000
Cash, end of year.....	\$ 92,000	\$ 860,000

The accompanying notes are an integral part of these financial statements.

F-6

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

	Year Ended June 30,	
	2005	2004
Supplemental disclosure of cash flow information:		
Cash paid for interest.....	\$ -	\$ -
Supplemental schedule of non-cash investing and financing activities:		
Issuance of common stock and warrants for services.....	\$ 342,000	\$ 2,789,000
Dividends payable on preferred stock.....	\$ 23,000	\$ 9,000
Deemed dividends on preferred stock.....	\$ 36,000	\$ -
Conversion of 605,000 shares of preferred stock to 605,000 shares of common stock.....	\$ 1,000	\$ -
Accrued legal fees paid as consideration for warrant exercise.....	\$ -	\$ 49,000
Legal fees prepaid as consideration for warrant exercise.....	\$ -	\$ 3,000
Write-off of notes receivable against reserve...	\$ -	\$ 177,000
Subscription receivable for conversion of warrants.....	\$ 57,000	\$ 40,000
Issuance of common stock in payment of dividends on preferred A stock.....	\$ 26,000	\$ -
Issuance of common stock for legal fee in connection with stock offering.....	\$ 24,000	\$ -
Subscription receivable for purchase of Class B preferred shares.....	\$ 91,000	\$ -

The accompanying notes are an integral part of these financial statements.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

F-7

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2005

Note A - Description of Business and Basis of Presentation

Description of Business:

AquaCell Technologies, Inc. was incorporated in Delaware on March 19, 1997 and its principal business activity is the manufacture and sale of products for water filtration and purification through its operating subsidiaries Aquacell Water, Inc. (formerly Water Science Technologies, Inc.) and to a lesser extent, Global Water-Aquacell Inc., currently an inactive company. Its Aquacell Media, Inc. subsidiary places coolers into various locations and sells targeted advertising on the bottle band of the permanently attached five-gallon bottle. AquaCell Technologies, Inc. and its wholly owned subsidiaries (the "Company") conduct substantially all of its business in the United States.

Going Concern:

The Company incurred net losses of \$3,888,000 and \$4,512,000 during the years ended June 30, 2005 and 2004, respectively. In addition, the Company had a working capital deficiency of \$1,671,000 and a stockholders' deficiency of \$91,000 at June 30, 2005. These factors, amongst others, raise substantial doubt about the Company's ability to continue as a going concern.

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.

The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

During the year ended June 30, 2005, the Company had successfully obtained external financing through private placements of equity securities and exercise of warrants.

The Company has developed a plan to address liquidity in several ways, namely:

- . Continue to raise capital through the sale or exercise of equity securities.
- . Continue to pursue the placement of our water cooler billboards in various locations.
- . Increase revenue through the sale of advertising on the band of the cooler's permanently attached five-gallon bottle.
- . Increase revenue through the sale of water systems and related

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

products.

Note B - Summary of Significant Accounting Policies

[1] Principles of consolidation:

The accompanying consolidated financial statements include the accounts of AquaCell Technologies, Inc., and its wholly owned subsidiaries. Such subsidiaries are Global Water Aquacell, Inc., currently an inactive company, incorporated December 21, 1998, Aquacell Water, Inc. (formerly Water Science Technologies, Inc.) acquired on March 19, 2002, and AquaCell Media, Inc., formed on September 10, 2001. Aquacell Media, Inc. had minimal revenues through June 30, 2005. All significant intercompany accounts and transactions have been eliminated in consolidation.

[2] Inventories:

Inventories are carried at the lower of cost or market, using the FIFO (first-in, first-out) method.

[3] Property and equipment and billboard coolers:

Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets which approximates three to five years.

Billboard coolers, manufactured by the Company, are stated at cost. Depreciation is computed using the straight-line method over their estimated useful life of five years, commencing with the date placed on location.

F-8

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note B - Summary of Significant Accounting Policies-(continued)

[4] Goodwill:

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in connection with our acquisition of Water Science Technologies, Inc. The Company has adopted Statement of Financial Accounting Standards No. 142 (SFAS 142), "Goodwill and Other Intangible Assets". Fair value of the reporting unit is determined by comparing the fair value of the unit with its carrying value, including goodwill. Impairment tests are performed using discounted cash flow analysis and estimates of sales proceeds. The annual evaluation of goodwill is performed as of June 30, the end of the Company's fiscal year. Impairment charges were \$74,000 and \$218,000 for the years ended June 30, 2005 and 2004, respectively.

[5] Patents:

The value of patents is amortized over nine years, their remaining useful lives at date of acquisition, using the straight-line method. Patents at June 30, 2005, are stated net of accumulated amortization of approximately \$143,000. Amortization expense was approximately \$22,000 for each of the years ended June 30, 2005 and 2004.

[6] Revenue recognition:

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Revenues are recorded at the time our products are shipped unless we agreed to install the products, in which case we recognize revenue at the time of installation. Advertising revenues are recognized on a straight-line basis over the term of the advertising contract.

[7] Advertising:

Advertising costs are expensed as incurred. Advertising expense for the years ended June 30, 2005 and 2004, was approximately \$0 and \$119,000, respectively.

[8] Use of estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

[9] Income taxes:

The Company accounts for income taxes using the asset and liability method described on SFAS No. 109, "Accounting For Income Taxes, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company's assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

[10] Net loss per common share:

Loss per common share is based upon the weighted average number of common shares outstanding during the year. Diluted loss per common share is the same as basic loss per share, as the effects of potentially dilutive securities (see Notes I (3) and I (5)) are antidilutive. Losses attributable to common stock have been adjusted for the preferred stock dividends.

F-9

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
June 30, 2005

Note B - Summary of Significant Accounting Policies-(continued)

[11] Long-lived assets:

The Company accounts for the impairment and disposition of long-lived assets in accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-lived Assets." In accordance with SFAS No. 144, long-lived assets to be held are reviewed whenever events or changes in circumstances indicate that their carrying value may not be recoverable. The Company periodically reviews the carrying value of long-lived assets to determine whether or not an impairment to such value has occurred, and has determined that as of June 30, 2005, that impairment, where appropriate, was recorded in the financial statements.

[12] Concentrations of credit risk:

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and trade accounts receivable. The Company performs ongoing credit evaluations of its customers' financial condition, but does not require collateral to support such receivables.

The Company utilizes a limited number of suppliers for certain components used in its products but has no long-term supply contracts with them.

[13] Financial instruments:

The carrying amounts of the Company's cash, accounts receivable, accounts payable, and customer deposits, approximate fair value because of the immediate or short-term maturity of these financial instruments.

[14] Stock based compensation:

The Company follows SFAS No. 123, "Accounting for Stock-Based Compensation." SFAS No. 123 establishes accounting and reporting standards for stock-based employee compensation plans. This statement allows companies to choose between the fair value-based method of accounting as defined in this statement and the intrinsic value-based method of accounting as prescribed by Accounting Principles Board Opinion No. 25 ("APB 25"), "Accounting for Stock Issued to Employees."

The Company has elected to continue to follow the accounting guidance provided by APB 25, as permitted for stock-based compensation relative to the Company's employees. Stock, warrants and options granted to other parties in connection with providing goods and services to the Company are accounted for under the fair value method as prescribed by SFAS No. 123.

In December 2002, the Financial Accounting Standard Board ("FASB") issued SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure - an Amendment of SFAS Statement No. 123". This statement amends SFAS No. 123 to provide alternative methods of transition for a voluntary change to the fair value-based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. SFAS No. 148 also requires that those effects be disclosed more prominently by specifying the form, content, and location of those disclosures. The provisions of SFAS No. 148 are effective for financial statements for the year ended June 30, 2003. SFAS No. 148 did not have a material impact on the Company's consolidated financial statements as the adoption of this standard does not require the Company to change and the Company does not plan to change to the fair value based method of accounting for stock-based compensation.

F-10

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note B - Summary of Significant Accounting Policies-(continued)

[14] Stock based compensation: (continued)

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

	For the Year Ended June 30,	
	2005	2004
Net loss applicable to common stockholders, as reported.....	\$ (4,001,000)	\$ (4,562,000)
Add: stock-based employee compensation expense included in reported net loss applicable to common stockholders.....	-	-
Less: total stock-based employee compensation expense determined under the fair value-based method of all awards.....	(416,000)	(672,000)
Proforma Net Loss Applicable to Common Stockholders.....	\$ (4,417,000)	\$ (5,234,000)
Basic and Diluted Net Loss Applicable to Common Stockholders:		
As reported.....	\$ (.24)	\$ (.40)
Proforma.....	\$ (.26)	\$ (.46)

The fair value during the year ended June 30, 2005 was estimated at the date of grant using the Black-Scholes option-pricing using the following weighted-average assumptions:

Assumptions	2005
Risk-free rate	3.1 %
Annual rate of dividends	0
Volatility	88 %
Average Life	7.2 years

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Our employee stock options have characteristics significantly different from those of traded options and changes in the subjective input assumptions can materially affect the fair value estimate. During 2005, the estimated fair value of the options granted was \$0.42 per unit.

[15] Shipping and handling fees and costs:

Shipping and handling fees and costs of approximately \$42,000 and \$21,000 for the years ended June 30, 2005 and 2004, respectively, are included in other expenses.

[16] Derivatives:

The Company recognizes all speculative derivatives on the balance sheet at fair value on the date the derivative instrument is entered into, with a corresponding charge to income (loss) from operations in accordance with SFAS-133. Subsequent changes to fair value are reflected in income (loss) from operations. Fair value is estimated at each balance sheet date using a Black-Scholes pricing model.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

F-11

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note B - Summary of Significant Accounting Policies-(continued)

[17] New accounting pronouncements:

In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Shared-Based Payment." SFAS 123(R) addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments. SFAS 123 (R) requires an entity to recognize the grant-date fair-value of stock options and other equity-based compensation issued to employees in the income statement. The revised statement generally requires that an entity account for those transactions using the fair-value-based method, and eliminates the intrinsic value method of accounting in APB 25, which was permitted under SFAS No. 123, as originally issued.

The revised statement requires entities to disclose information about the nature of the share-based payment transactions and the effects of those transactions on the financial statements.

SFAS No. 123 (R) is effective for small business issuer's financial statements for the first interim or annual reporting period that begins after December 15, 2005, with early adoption encouraged.

The Company is currently evaluating the impact that this statement will have on its financial condition or results of operations.

Emerging Issue Task Force (EITF) Issue 04-8, "The Effect of Contingently Convertible Instruments on Diluted Earnings per Share." The EITF reached a consensus that contingently convertible instruments, such as contingently convertible debt, contingently convertible preferred stock, and other such securities should be included in diluted earnings per share (if dilutive) regardless of whether the market price trigger has been met. The consensus is effective for reporting periods ending after December 15, 2004.

The adoption of this pronouncement did not have a material effect on the Company's financial statements.

In May 2005, the FASB issued Statement of Financial Accounting Standards No. 154, "Accounting Changes and Error Corrections--a replacement of APB Opinion No. 20 and FASB Statement No. 3" ("SFAS 154"). This Statement replaces APB Opinion No. 20, "Accounting Changes," and FASB Statement No. 3, "Reporting Accounting Changes in Interim Financial Statements," and changes the requirements for the accounting for and reporting of a change in accounting principle. This Statement applies to all voluntary changes in accounting principle. It also applies to changes required by an accounting pronouncement in the unusual instance that the pronouncement does not include specific transition provisions. When a pronouncement includes specific transition provisions, those provisions should be followed. SFAS 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005. Consequently, the Company will adopt the provisions of SFAS 154 for its fiscal year beginning July 1, 2006. Management currently believes that adoption of the provisions of SFAS No. 154 will not have a material impact on the Company's consolidated financial statements.

[18] Reclassifications:

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Certain items in these financial statements have been reclassified to conform to the current period presentation. These reclassifications had no impact on our results of operations, stockholders' deficiency or cash flows.

Note C - Subscriptions Receivable:

At June 30, 2005 the subscriptions receivable consisted of \$91,000 resulting from the sale of shares in the Class B Preferred Stock private placement and \$57,000 from the exercise of common stock purchase warrants. All of the subscriptions receivable were paid prior to the issuance of the financial statements and, accordingly, are classified as current assets.

F-12

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note D - Inventories:

Inventories consist of the following at June 30, 2005:

Raw materials.....	\$ 12,000
Work in progress.....	1,000

	\$ 13,000
	=====

Note E - Property and Equipment and Billboard Coolers:

Property and equipment is summarized as follows at June 30, 2005:

Billboard coolers- on location.....	\$ 539,000
Billboard coolers- not on location.....	538,000
Billboard coolers parts- not on location.....	157,000
Furniture and fixtures.....	36,000
Equipment - office.....	101,000
Machinery and equipment.....	131,000
Leasehold improvements.....	12,000
Truck.....	11,000

	1,525,000
	314,000

Less accumulated depreciation.....	\$ 1,211,000
	=====

Depreciation expense was approximately \$57,000 and \$23,000 for the year ended June 30, 2005 and 2004, respectively.

Note F - Accrued Liabilities

At June 30, 2005 the accrued liabilities consisted of officers' salaries of \$260,000, payroll taxes withheld of \$390,000, accrued payroll taxes of \$134,000, accrued penalties and interest on taxes payable of \$191,000 and other accrued liabilities of \$99,000. As of June 30, 2005 five tax liens have been filed; four Federal tax liens of approximately \$292,000 and one state tax lien of approximately \$26,000.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Note G - Loan Payable- Related Party

At June 30, 2005 loan payable to a related party consisted of an unsecured demand loan of \$100,000, from a director of the Company, with interest at the rate of 8% per annum. In connection with the loan the lender received 25,000 common stock purchase warrants (See Note I (5)).

Note H - Deferred Payable

At June 30, 2005, the deferred payable represented the unpaid balance due to a private company for the return and cancellation of all exclusive distribution and marketing rights previously held under a distribution agreement. The unpaid balance of \$473,000, of which \$22,000 is classified as a current liability, represented a return to the private company of \$1,339,000 reduced by \$866,000 received from the sales of 451,807 shares of AquaCell common stock that it owned (See Note N (2)). This amount is payable solely from 5% of the future revenues to generated by our Global Water-Aquacell subsidiary. The Company recognized a \$333,000 fair value adjustment of this payable during the year ended June 30, 2004.

Note I - Equity Transactions

[1] Series A Convertible Preferred Stock:

During the years ended June 30, 2005 and 2004, 605,000 and 510,000 shares, respectively, of Series A Convertible Preferred Stock were converted into 605,000 and 510,000 shares of Common Stock of the Company, respectively.

F-13

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2004

Note I - Equity Transactions-(continued)

[2] Series B Convertible Preferred Stock:

During June 2005 the Company completed a private placement of 718,000 shares of its newly designated Series B Convertible Preferred Stock. The offering consisted of 718,000 shares of class B convertible preferred stock at a price of \$0.34 per share and 279,500 Class B common stock purchase warrants exercisable at \$0.50 per share. The Series B Convertible Preferred Stock carries an \$.08 per share annual dividend and is convertible into the Company's common stock on a one for one basis. The first year's dividend was prepaid in full at the time of the sale. Based on the effective conversion price of the preferred stock using a relative fair value of \$39,000 attributable to the warrants the Company recognized a beneficial conversion feature of \$36,000 as a deemed dividend to the holders of the convertible preferred stock. In connection with this offering the Company received net proceeds of \$168,000 after dividends paid of \$57,000 and expenses of \$19,000. In addition the Company issued 24,891 Class B common stock purchase warrants exercisable at \$0.50 per share to the placement agent.

[3] Stock option plans:

During August 1998, the Company adopted the 1998 Incentive Stock Plan (the "Plan") under which options (either incentive or nonqualified), stock

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

appreciation rights, stock and other awards, covering an aggregate amount of 1,000,000 shares of common stock, may be granted to officers, directors, employees and consultants of the Company. The exercise price established for any awards granted under the Plan, shall be determined by a Compensation Committee appointed by the Company's Board of Directors. The exercise price of incentive stock options cannot be less than 100% (110% for 10% or greater shareholder employees) of the fair market value ("FMV") at the date of grant and the exercise price of nonqualified options cannot be less than 85% of the FMV at the date of grant. The exercise period of incentive options cannot extend beyond 10 years from the date of grant and nonqualified options cannot extend beyond 15 years from the date of grant. At the December 2, 2003 annual meeting the shareholders approved the increase in issuable shares from 1,000,000 to 2,000,000 in the plan.

During January 2002, the Board of Directors adopted a Director's Option Plan covering an aggregate amount of 500,000 shares of common stock. As of June 30, 2005, 360,000 options have been granted under this plan.

A summary of stock option activity under both plans is as follows:

	Year Ended June 30,			
	2005		2004	
	Shares	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
Balance July 1.....	1,066,000	\$1.10	506,000	\$0.90
Options granted.....	985,000	0.51	620,000	1.26
Options cancelled.....	(115,500)	1.06	(25,000)	1.02
Options exercised.....	0	-	(35,000)	0.94
Balance, June 30.....	1,935,500	\$0.80	1,066,000	\$1.10
Exercisable, June 30.....	562,000	\$1.01	377,000	\$1.07

During the year ended June 30, 2004 options were exercised for 35,000 shares and the Company received proceeds of \$33,000. No options were exercised during the year ended June 30, 2005.

F-14

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note I - Equity Transactions-(continued)

[3] Stock option plans (continued)

The following table presents information relating to stock options outstanding at June 30, 2005:

Options Outstanding	Options Exercisable
Weighted-	

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Exercise Price	Shares	Weighted-Average Exercise Price	Average Remaining Life in Years	Shares	Weighted-Average Exercise Price
0.37	35,000		7.0	-	
0.40	190,000		7.2	40,000	
0.41	42,500		6.8	-	
0.55	717,500		6.7	40,000	
0.60	140,500		4.5	56,000	
0.65	30,000		7.6	30,000	
1.00	60,000		9.2	60,000	
1.15	85,000		7.0	73,000	
1.16	70,000		3.9	42,000	
1.24	515,000		6.0	171,000	
1.45	50,000		8.8	50,000	
	-----		-----	-----	
	1,935,500	\$0.80	6.5	562,000	\$1.01
	=====		=====	=====	

If the options had been accounted for under SFAS 123, net loss attributable to common stockholders for the years ended June 30, 2005 and 2004, would have been \$(4,417,000) or \$(0.26) per common share, and \$(5,234,000) or \$(0.46) per common share, respectively. The fair value of options granted during the years ended June 30, 2005 and June 30, 2004, was \$0.42 and \$0.27 per share on the date of grant, respectively. The options were valued utilizing the Black-Scholes valuation method using the following assumptions: risk-free interest rate of 3.1% and 4.99%, volatility of 88% and 42% and expected lives of five and three years, respectively.

[4] Issuances of common stock:

Between July and September 2003 the Company completed a private placement of 1,703,000 shares of its common stock. The offering consisted of one share of common stock at \$1.50 per share and one common stock purchase warrant exercisable at \$4.00 per share. The Company received gross proceeds from the offering of \$2,555,000 and expenses of the offering were \$259,000. In connection with the offering the placement agent received 341,000 common stock purchase warrants exercisable at \$4.00 per share.

During February 2004 the Company completed a private placement of 650,000 shares of its common stock. The offering consisted of one share of common stock at \$1.00 per share and one common stock purchase warrant exercisable at \$1.75 per share. The Company received gross proceeds from the offering of \$649,000 and expenses of the offering were \$79,000. In connection with the offering the placement agent received 87,000 common stock purchase warrants exercisable at \$1.75 per share.

During the year ended June 30, 2004 the Company issued 35,000 shares of common stock in connection with the exercise of employee stock options. The Company received proceeds of \$33,000.

During December 2003 the Company issued 1,100,000 shares of common stock in connection with the exercise of 1,100,000 common stock purchase warrants issued for marketing and consulting agreements (see Note N(2)). The Company received proceeds of \$11,000.

F-15

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Note I - Equity Transactions-(continued)

[4] Issuances of common stock: (continued)

During April 2004 the Company completed a private placement of 652,000 shares of its common stock. The offering consisted of one share of common stock at \$1.15 per share and one common stock purchase warrant exercisable at \$1.90 per share. The Company received gross proceeds from the offering of \$760,000 and expenses of the offering were \$85,000. In connection with the offering the placement agent received 100,000 common stock purchase warrants exercisable at \$1.90 per share.

During June 2004 the Company issued 965,000 shares of common stock in connection with the repricing of 965,000 common stock purchase warrants issued in a private placement completed during July - September 2003 (See Note H(5)). The \$4.00 warrants were repriced to \$0.83. The Company received gross proceeds of \$812,000 from the warrant exercise and expenses were \$79,000. In connection with the exercise the Company issued new common stock purchase warrants for 383,000 shares of its common stock exercisable at \$4.00 per share and 582,000 shares of its common stock exercisable at \$2.00 per share and repriced an additional 401,000 existing warrants from an exercise price of \$4.00 to an exercise price of \$2.00 per share.

In connection with a three-year service agreement (see Note N (2)) the Company issued 100,000 shares of its common stock valued at \$82,000. There was no amortization during the year ended June 30, 2004. Amortization amounted to \$16,000 for the year ended June 30, 2005.

During August 2004 the Company amended a February 2004 consulting agreement to provide for additional compensation of 100,000 common shares. These shares were valued at \$66,000 based upon closing market price at the date of issuance. Such amount will be amortized to expense over the remaining term of the agreement. Amortization amounted to \$17,000 for the year ended June 30, 2005.

During September 2004 the Company issued an aggregate of 457,000 shares of common stock in connection with the exercise of 457,000 common stock purchase warrants issued in previously completed private placements. Warrants with exercise prices of \$2.00 and \$4.00 were repriced to \$.70 and \$.56. The Company realized gross proceeds of \$286,000 and expenses were \$32,000 in connection with the exercise. New common stock purchase warrants were issued for 247,000 shares of common stock exercisable at \$.90 per share and 210,000 shares of common stock exercisable at \$.95 per share and an additional 210,000 shares of common stock exercisable at \$4.00 per share.

During October and November 2004 the Company issued an aggregate of 693,000 shares of common stock in connection with the exercise of 693,000 common stock purchase warrants issued in previously completed private placements. Warrants with exercise prices ranging from \$.80 to \$4.00 were repriced to prices ranging from \$.55 to \$.68. The Company realized gross proceeds of \$434,000 and expenses were \$43,000 in connection with the exercise. New common stock purchase warrants were issued for 600,000 shares of common stock exercisable at \$.80 per share and 93,000 shares of common stock exercisable at \$.90 per share.

During November 2004 the Company amended an August 2003 consulting agreement to provide for additional compensation of 300,000 common shares. These shares were valued at \$177,000 based upon closing market price at the date of issuance. The original agreement was extended for a two year period and the remaining aggregate deferred compensation in the amount of \$410,632 will be amortized to expense over the remaining term of the agreement. Amortization amounted to \$70,000 for the year ended June 30, 2005.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

During November 2004 the Company issued 40,000 shares of common stock in payment of legal fees in connection with the January 2005 filing of a registration statement. The shares were valued at \$24,000 based upon the closing market price at the date of issuance.

F-16

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note I - Equity Transactions-(continued)

[4] Issuances of common stock: (continued)

During December 2004 the Company issued an aggregate of 974,000 shares of common stock in connection with the exercise of 974,000 common stock purchase warrants issued in previously completed private placements. Warrants with exercise prices ranging from \$1.75 to \$4.00 were repriced to \$.55. The Company realized gross proceeds of \$536,000 and expenses were \$54,000 in connection with the exercise. New common stock purchase warrants were issued for 974,000 shares of common stock exercisable at \$.75. In connection with the transaction 301,000 warrants were repriced from \$2.00 and \$4.00 to \$1.00.

During December 2004 605,000 shares of class A preferred stock were converted into 605,000 shares of common stock.

During December 2004 the Company issued an aggregate of 35,000 shares of common stock in payment of dividends on preferred stock in the amount of \$26,000 for the quarters ended June 2004, September 2004 and December 2004.

During December 2004 the Company issued 50,000 shares of common stock in connection with an employment agreement. These shares were valued at \$20,000 based upon the closing market price at the date of issuance. Such amount was charged to operations for the year ended June 30, 2005.

During January 2005 the Company issued an aggregate of 100,000 shares of common stock in connection with the exercise of 100,000 common stock purchase warrants issued in previously completed private placements. Warrants with an exercise price of \$.80 were repriced to \$.55. The Company realized gross proceeds of \$55,000 and expenses were \$5,000 in connection with the exercise. New common stock purchase warrants were issued for 100,000 shares of common stock exercisable at \$.75.

During March 2005 the Company completed a private placement of 566,667 shares of its common stock. The offering consisted of one share of common stock at a price of \$.30 and one common stock purchase warrant exercisable at \$.75 per share. The warrant contains a call feature. The Company received proceeds of \$170,000 and there were no expenses incurred.

During April 2005 the Company completed a private placement of 416,667 shares of its common stock. The offering consisted of one share of common stock at a price of \$.30 and one common stock purchase warrant exercisable at \$.75 per share. The Company received proceeds of \$125,000 and there were no expenses incurred.

During April 2005 the Company issued 50,334 shares of common stock in connection with the exercise of 50,334 common stock warrants. Warrants with an exercise price of \$.90 were repriced to \$.32. The Company realized gross proceeds of \$16,000 and expenses were \$3,000 in connection with the exercise. New common stock purchase warrants were issued for 100,668 shares of common

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

stock exercisable at \$.75 per share.

[5] Issuances of common stock purchase warrants:

In connection with a distribution agreement (See Note N (2)), the Company issued warrants to purchase 300,000 shares of the Company's common stock to be exercisable for a five-year period (100,000, 100,000, and 100,000 at exercise prices of \$5.00, \$6.00, and \$7.00, per share respectively). The Company estimated the fair value of these warrants to be \$283,000, utilizing the Black-Scholes valuation method using the following assumptions: a risk-free interest rate of 3.1%, volatility of 33.33%, and a term of five years. Such amount is being amortized over five years. During the year ended June 30, 2003 the agreement was amended and the 100,000 warrants exercisable at \$6.00 per share and the 100,000 warrants exercisable at \$7.00 per share were returned to the Company. The unamortized portion of these warrants, in the amount of \$110,000, was written off to additional paid in capital. Amortization amounted to \$54,000 for the year ended June 30, 2005 and \$24,000 for the year ended June 30, 2004.

F-17

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
June 30, 2005

Note I - Equity Transactions-(continued)

[5] Issuances of common stock purchase warrants: (continued)

In connection with a one-year credit facility agreement, entered into in August 2002, the Company issued warrants to purchase 160,000 shares of common stock to be exercisable for a five-year period at \$.78 per share. The Company estimated the fair value of these warrants to be \$43,000 utilizing the Black-Scholes valuation method using the following assumptions: a risk-free interest rate of 3.1%, volatility of 33.33% and a term of five years. Such amount is being amortized to expense over one year. Amortization amounted to \$7,000 during the year ended June 30, 2004.

In connection with a one-year consulting agreement, entered into in March 2003, the Company issued a warrant to purchase 150,000 shares of common stock to be exercisable for a two-year period at \$1.00 per share. The Company estimated the fair value of this warrant to be \$12,000 utilizing the Black-Scholes valuation method using the following assumptions: a risk-free interest rate of 3.1%, volatility of 33.33% and a term of two years. Such amount is being amortized to expense over one year. Amortization amounted to \$9,000 during the year ended June 30, 2004.

In connection with marketing and consulting agreements with five separate entities, entered into in August 2003, the Company issued warrants to purchase 1,250,000 shares of common stock to be exercisable at \$.01 per share. The Company estimated the fair value of these warrants to be \$2,564,000 utilizing the Black-Scholes valuation method using the following assumptions: a risk-free interest rate of 3.1%, volatility of 33.33% and a term of five years. Such amount is being amortized to expense over three years. Amortization for the years ended June 30, 2005 and 2004 amounted to \$651,000 and \$926,000, respectively.

In connection with a three year consulting agreement, entered into in February 2004, the Company issued a warrant to purchase 150,000 shares of common stock to be exercisable for a five-year period at \$1.22 per share. The Company estimated the fair value of this warrant to be \$143,000 utilizing the Black-Scholes valuation method using the following assumptions: a risk free interest

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

rate of 3.1%, volatility of 106.9 % and a term of five years. Such amount is being amortized to expense over three years. Amortization amounted to \$48,000 for the year ended June 30, 2005 and \$17,000 for the year ended June 30, 2004.

In connection with a warrant repricing, completed in June 2004, the Company issued common stock purchase warrants for 383,000 shares of its common stock exercisable at \$4.00 per share and for 582,000 shares of its common stock exercisable at \$2.00 per share (See Note I(4)).

During June 2004 an aggregate of 965,000 common stock purchase warrants previously issued in a July through September 2003 private placement were repriced from an exercise price of \$4.00 per share to an exercise price of \$0.83 per share. The Company realized gross proceeds of \$812,000 and expenses were \$79,000 in connection with the repricing. New common stock purchase warrants were issued for 383,000 shares of common stock exercisable at \$4.00 per share and 582,000 shares of common stock exercisable at \$2.00 per share and an additional 401,000 existing warrants were repriced from an exercise price of \$4.00 per share to an exercise price of \$2.00 per share.

During August 2004 the Company issued 50,000 common stock purchase warrants at a price of \$.66 per share in connection with performance under an existing consulting agreement. The Company estimated the fair value of these warrants to be \$25,000 utilizing the Black-Scholes valuation method using the following assumptions; a risk-free interest rate of 3.1%, volatility of 98.71% and a term of five years. Such amount will be amortized over a period of 31 months. Amortization amounted to \$9,000 for the year ended June 30, 2005.

In connection with a warrant repricing, completed in September 2004, the Company issued common stock purchase warrants for 247,000 shares of its common stock exercisable at \$.95 per share and for 210,000 shares of its common stock exercisable at \$4.00 per share.

In connection with a warrant repricing, completed in November 2004, the Company issued common stock purchase warrants for 600,000 shares of its common stock exercisable at \$.80 per share and 93,000 shares of its common stock exercisable at \$.90 per share.

F-18

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note I - Equity Transactions-(continued)

[5] Issuances of common stock purchase warrants: (continued)

During November 2004 the Company amended an August 2003 nonexclusive finders arrangement to provide for the issuance of 225,000 common stock purchase warrants at an exercise price of \$.85 per share. The Company estimated the fair value of these warrants to be \$143,000 utilizing the Black-Scholes valuation method using the following assumptions; a risk-free interest rate of 3.1%, volatility of 98.71% and a term of 5 years. The amount has been charged to Additional Paid-In Capital as a cost of raising capital.

During December 2004 the Company issued 100,000 common stock purchase warrants at a price of \$.40 per share in connection with two consulting agreements. The Company estimated the fair value of these warrants to be \$30,000 utilizing the Black Scholes valuation method using the following assumptions; a risk-free interest rate of 3.1%, volatility of 98.71% and a term of 5 years. Such amount will be amortized over a five year period. Amortization of \$2,000 was recorded during the year ended June 30, 2005.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

In connection with a warrant repricing, completed in December 2004, the Company issued common stock purchase warrants for 974,000 shares of its common stock exercisable at \$.75 per share.

In connection with a warrant repricing, completed in January 2005, the Company issued common stock purchase warrants for 100,000 shares of its common stock exercisable at \$.75 per share.

In connection with a private placement of common stock, completed in March 2005, the Company issued common stock purchase warrants for 566,667 shares of its common stock exercisable at \$.75 per share.

In connection with a private placement of common stock, completed in April 2005, the Company issued common stock purchase warrants for 416,667 shares of its common stock exercisable at \$.75 per share.

In connection with a warrant repricing, completed in April 2005, the Company issued common stock purchase warrants for 100,000 shares of its common stock exercisable at \$.75 per share.

During June 2005 the Company issued 25,000 common stock purchase warrants at a price of \$.40 per share to a director of the Company in connection with a \$100,000 loan to the Company. The Company estimated the fair value of these warrants to be \$5,000 utilizing the Black-Scholes valuation method using the following assumptions; a risk-free interest rate of 3.1%, volatility of 50.06% and a term of 5 years. This amount was charged to operations during the year ended June 30, 2005 (See Note G).

During June 2005 the Company issued 100,000 common stock purchase warrants at a price of \$.37 per share in connection with an investor relations agreement. The Company estimated the fair value of these warrants to be \$19,000 utilizing the Black-Scholes valuation method using the following assumptions; a risk-free interest rate of 3.1%, volatility of 50.06% and a term of 5 years. There was no amortization taken during the year ended June 30, 2005 since the agreement became effective on July 1, 2005 (See Note O(2)).

In connection with a private placement of Class B preferred stock, completed in June 2005, the Company issued Class B common stock purchase warrants for 279,500 shares of its common stock exercisable at \$.50 per share and an additional 24,891 shares of its common stock exercisable at \$.50 per share to the placement agent.

All warrants issued in connection with private placements and warrant repricings were issued to non-employees of the Company.

F-19

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note I - Equity Transactions-(continued)

[5] Issuances of common stock purchase warrants: (continued)

At June 30, 2005, the Company had warrants outstanding as follows:

Exercise Price	Shares	Expiration Date
-----	-----	-----
\$ 0.01	150,000	August 2008
0.37	100,000	June 2010

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

0.40	100,000	December 2009
0.40	25,000	June 2010
0.50	150,000	March 2007
0.50	304,391	June 2010
0.66	50,000	August 2009
0.75	974,465	December 2009
0.75	100,000	January 2010
0.75	566,667	March 2010
0.75	517,336	April 2010
0.78	160,000	August 2007
0.80	150,000	October 2009
0.80	200,000	November 2009
0.85	225,000	September 2009
0.90	147,000	September 2009
0.90	93,478	October 2009
0.95	110,140	September 2009
1.00	300,667	December 2009
1.16	685,000	March 2008
1.22	150,000	February 2009
1.60	500,000	May 2008
1.75	600,000	February 2009
1.90	608,695	April 2009
2.00	134,033	June 2009
2.00	50,334	September 2008
3.00	100,000	June 2007
3.30	100,000	May 2007
4.00	20,000	September 2008
4.00	93,473	September 2009
4.00	110,000	June 2009
4.20	200,000	May 2006
4.50	50,000	October 2006
5.00	100,000	October 2006
5.00	100,000	June 2007
5.50	50,000	October 2006
8.25	120,000	February 2006

8,195,679		
=====		

At June 30, 2005, the weighted average exercise price of the outstanding warrants was \$1.51 and the weighted average remaining contractual life of the warrants was 3.71 years.

F-20

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note I - Equity Transactions-(continued)

[6] Shares reserved:

At June 30, 2005, the Company has reserved 10,919,000 shares of common stock for issuance upon conversion of preferred stock and exercise of options and warrants.

Note J - Spin-off of Subsidiary

During December 2004 the Company announced the spin-off of its inactive Aquacell Water subsidiary to its common stockholders on a share for share basis. It was anticipated that Aquacell Water might acquire our Water Science

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Technologies, Inc. subsidiary. In July 2005 the Board of Directors changed the structure of the anticipated spin-off. (See Note Q (4)). Aquacell Water has no assets, liabilities or operations and, accordingly, the spin-off would have no material effect on our financial statements.

Note K - Income Taxes:

At June 30, 2005, the Company had available federal net operating loss carryforwards to reduce future taxable income, if any, of approximately \$13,450,000. The net operating loss carryforwards expire at various dates through 2025.

At June 30, 2005, the Company has a deferred tax asset of approximately \$5,783,000, representing the benefit of its net operating loss carryforwards. The Company has not recorded a tax benefit because realization of the benefit is uncertain and therefore a valuation allowance has been fully provided against the deferred tax asset. The difference between the federal statutory rate of 34% and the Company's effective tax rate of 0% is due to an increase in the valuation allowance of \$1,139,000 and \$1,118,000 in 2005 and 2004, respectively.

Note L - Other Costs and Expenses

Other costs and expenses consisted of the following:

	Year Ended June 30,	
	2005	2004
Manufacturing expenses - billboard coolers.....	\$ 481,000	\$ 482,000
Rent.....	100,000	119,000
Telephone and utilities.....	46,000	56,000
Travel.....	81,000	67,000
Business promotion.....	102,000	181,000
Consulting and service fees and expenses.....	50,000	123,000
Insurance.....	91,000	75,000
Vehicle expenses.....	84,000	105,000
Listing fees.....	88,000	50,000
Exchange fees, transfer agent fees and investor fees and expenses..	58,000	40,000
Office expenses, postage and supplies.....	108,000	96,000
Depreciation and amortization.....	73,000	30,000
Other expenses.....	231,000	278,000
	<u>\$1,593,000</u>	<u>\$ 1,702,000</u>

Note M - Interest Expense:

Included in interest expense is penalties and interest on delinquent payroll taxes payable in the amount of \$78,000 and \$96,000 for the years ended June 30, 2005 and 2004, respectively.

F-21

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
June 30, 2005

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

Note N - Segment Data

The Company has two reportable segments; water systems and related products and advertising.

The following table presents information about the Company's business segments for the year ended June 30, 2005:

	Water Systems and Related Products	Advertising	Total
	-----	-----	-----
Net revenue.....	\$ 807,000	\$ 30,000	\$ 837,000
Loss from operations.....	\$ (1,602,000)	\$ (2,195,000)	\$ (3,797,000)
Stock based compensation.....	\$ 369,000	\$ 804,000	\$ 1,173,000
Depreciation and amortization.....	\$ 11,000	\$ 68,000	\$ 79,000
Identifiable assets.....	\$ 1,149,000	\$ 1,234,000	\$ 2,383,000

Segment accounting was not applicable to the year ended June 30, 2004.

Note O - Commitments and Contingencies

[1] Lease commitments:

The Company occupies manufacturing office space in California and Arizona, under noncancellable operating leases. The leases in California have been extended to April 30, 2006. As of June 30, 2005, future minimum commitments under office and equipment operating leases are as follows:

Year Ending June 30,	

2006	\$ 165,000
2007	20,000

	\$ 185,000
	=====

Rent expense under office and equipment leases amounted to approximately \$198,000 and \$176,000 for the years ended June 30, 2005 and 2004, respectively.

[2] Consulting agreements:

On May 30, 2003 the Company negotiated the return and cancellation of all exclusive distribution and marketing rights under the distribution agreement and joint venture agreement, with a private company, the return of 100,000 warrants exercisable at \$6.00 per share and the return of 100,000 warrants exercisable at \$7.00 per share. In exchange AquaCell granted the private company the right to continue to sell Global Water-Aquacell's products on a non-exclusive basis in those areas in which it retains salesmen. It was agreed that the private company would realize a return of \$1,339,000 from sales of the 451,807 shares of AquaCell common stock that it owns and, if required, from 5% of future revenues to be generated by our Global Water-Aquacell subsidiary (See Note H).

During August 2003 the Company entered into marketing and consulting agreements with five separate entities. Consideration for one of these agreements included cash fees of \$45,000 paid over a three-month period. In addition, 1,250,000 warrants to purchase common stock of the Company exercisable

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

for five years at a price of \$.01 per share, were issued for all these agreements.

During February 2004 the Company entered into a three year consulting agreement. Consideration for this agreement was 150,000 warrants to purchase shares of common stock of the Company exercisable for five years at a price of \$1.22 per share (See Note I(4)).

During June 2004 the Company entered into a three-year service agreement. The agreement calls for a cash payment of \$6,000 per month over the term of the agreement, and the issuance of 100,000 shares of the Company's common stock (See Note I(3)).

F-22

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note O - Commitments and Contingencies-(continued)

[2] Consulting agreements: (continued)

During December 2004 the Company entered into five year consulting agreements with two separate entities. Consideration for these agreements was 100,000 warrants to purchase shares of common stock of the Company exercisable for five years at a price of \$.40 per share (See Note I(5)).

During June 2005 the Company entered into a month-to-month investor relations agreement, effective July 1, 2005. Consideration for the agreement was \$5,500 per month and 100,000 warrants to purchase shares of common stock of the Company exercisable for five years at a price of \$.37 per share (See Note I (5)). The agreement will automatically renew on a monthly basis, unless terminated by either party in writing upon 30 days notice.

[3] Employment agreements

The Company has employment agreements with various executives and employees of the Company which expire at various dates through January, 2008. These agreements provide for aggregate minimum salaries of \$501,000 for the year ending June 30, 2006. The agreements also provide for incentive bonuses based upon achievement of certain milestones

Effective July 2002 the Company entered into a five-year employment contract with an officer of Aquacell Water. The contract called for a minimum annual salary of \$100,000. The contract was terminated in April 2005 in accordance with the provisions of the agreement and the Company will pay \$33,000 during the year ending June 30, 2006.

[4] Legal Proceedings

From time to time, the Company is named in legal actions in the normal course of business. In the opinion of management, the outcome of these matters, if any, will not have a material impact on the financial condition or results of operations of the Company.

Note P - Major Customers and Suppliers

During the year ended June 30, 2005 the Company derived approximately 33% of its revenues from two customers and purchased approximately 12% of its

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

materials from one vendor.

Note Q - Subsequent Events

[1] Equity Transactions

During July 2005 the Company issued 533,333 shares of its common stock in connection with the exercise of 533,333 common stock warrants. Warrants with exercise prices ranging from \$.75 to \$1.00 were repriced to \$.30. The Company realized gross proceeds of \$160,000 and expenses were \$16,000 in connection with the exercise. New common stock purchase warrants were issued for 533,333 shares of common stock exercisable at \$.50 per share.

During August 2005 the Company completed a private placement of 900,000 shares of its common stock. The offering consisted of one share of common stock at a price of \$.30 per share and one-half common stock purchase warrant exercisable at \$.60 per share. The Company received proceeds of \$270,000 and there were no expenses incurred.

During August 2005 the Company completed a private placement of 200,000 shares of Series B Convertible Preferred Stock. The offering consisted of 200,000 shares of Class B convertible preferred stock exercisable at \$.34 and 50,000 Class B common stock purchase warrants exercisable at \$.50 per share. The first year annual dividend of \$.08 per share was prepaid in full at the time of the placement. The Series B convertible preferred stock is convertible into the Company's common stock on a share for share basis. In connection with this offering the Company received net proceeds of \$52,000 after dividends paid of \$16,000. There were no expenses in connection with this offering.

F-23

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued) June 30, 2005

Note Q - Subsequent Events-(continued)

[1] Equity Transactions (continued)

During September 2005 the Company issued an aggregate of 1,841,512 shares of common stock in connection with the exercise of 1,841,512 common stock warrants. Warrants with exercise prices ranging from \$.50 to \$2.00 were repriced to prices ranging from \$.30 to \$.45. The Company realized gross proceeds of \$653,000 and expenses were \$65,000 in connection with the exercises. New common stock purchase warrants were issued for 524,512 shares of common stock exercisable at \$.70 per share, 868,333 exercisable at \$.50 per share, 365,000 exercisable at \$.55 per share and 83,667 exercisable at \$.65 per share.

During September 2005 the Company completed a private placement for 333,333 shares of its common stock. The offering consisted of one share of common stock at a price of \$.30 per share and one common stock purchase warrant exercisable at \$.50 per share. The Company realized gross proceeds of \$100,000 and expenses of the offering amounted to \$10,000. In addition the Company issued 13,333 common stock purchase warrants, exercisable at \$.50 per share, to the placement agent. The Company has committed to file a registration statement to include these shares by October 17, 2005 and will incur a monthly penalty of \$10,000 for failure to file.

During September 2005 the Company completed a private placement for 150,000 shares of its common stock. The offering consisted of one share of common stock at a price of \$.38 per share and one common stock purchase warrant

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10KSB

exercisable at \$.75. The Company realized gross proceeds of \$57,000 and there were no offering expenses.

[2] Increase in Authorized Capitalization

On July 19, 2005 the Board of Directors approved an amendment to the Company's Certificate of Incorporation to permit the Company to issue up to 100,000,000 shares of common stock.

[3] Amendment to 1998 Incentive Stock Plan

On October 10, 2005 the Board of Directors approved an increase in the 1998 Incentive Stock Plan's shares reserved for issuance from 2,000,000 to 3,000,000.

The resolutions approved by the Board of Directors in [2] and [3] above are subject to stockholder approval.

[4] Spin-off of Subsidiary

On July 19, 2005 the Board of Directors approved that in place of the Company's spin-off of its inactive Aquacell Water subsidiary (See Note J) management reincorporate its Water Science Technologies subsidiary in Delaware and change its name to Aquacell Water, Inc. Furthermore, this subsidiary will undertake to file a Form 10 registration statement with the possibility of spinning this company off to its common stockholders on a share for share basis. However, there is no assurance that this spin-off will occur.

F-24